StockData
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc. (TARA) stock

TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$2.32−0.06 (-2.52%)

Close on Nov 17, 2026Market cap $137.10MP/E –Yield –

Earnings

Protara Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 9, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.35
-$0.31 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Protara Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 9, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 6, 2026before the open––-$0.35Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026before the open––-$0.36Release
Q1 FY2026ended Mar 31, 2026May 13, 2026before the open–––Release
Q4 FY2025ended Dec 31, 2025Mar 10, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025before the open––-$0.31Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025before the open––-$0.35Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open––-$0.29Release
Q4 FY2024ended Dec 31, 2024Mar 5, 2025before the open––-$0.48Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open––-$0.50Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024before the open––-$0.45Release
Q1 FY2024ended Mar 31, 2024May 2, 2024before the open––-$0.97Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Protara Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Protara Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Protara Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Update
  6. Update
  7. Update
  8. Update
  9. Update
  10. Update
  11. Update
  12. Update
  13. Results
  14. Results
  15. Results

See a number that looks wrong?